Evidence map›Paper›PMID 41403359›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators.

Keita Ito, Yoshiyuki Manabe, Shino Ohshima, Masatoshi Maeki, Manabu Tokeshi, Hiroshi Inaba, Kazunori Matsuura, Kazuya Kabayama, Yoshie Kametani, Koichi Fukase

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keita ItoDepartment of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Yoshiyuki ManabeDepartment of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Shino OhshimaSchool of Medicine, Tokai University, Isehara, Kanagawa, 259-1193, Japan.
Masatoshi MaekiDivision of Applied Chemistry, Faculty of Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan.
Manabu TokeshiDivision of Applied Chemistry, Faculty of Engineering, Hokkaido University, Sapporo, Hokkaido, 060-8628, Japan.
Hiroshi InabaDepartment of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-Minami, Tottori, 680-8552, Japan.
Kazunori MatsuuraDepartment of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, 4-101 Koyama-Minami, Tottori, 680-8552, Japan.
Kazuya KabayamaDepartment of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.
Yoshie KametaniSchool of Medicine, Tokai University, Isehara, Kanagawa, 259-1193, Japan.
Koichi FukaseDepartment of Chemistry, Graduate School of Science, The University of Osaka, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan.ORCID 0000-0001-8844-0710

Funding

Japan Initiative for World-leading Vaccine Research and Development CentersJapan Science and Technology Agency JPMJCR20R3Japan Society for the Promotion of Science 20H04709Japan Society for the Promotion of Science 20H05675Japan Society for the Promotion of Science 21H05074Japan Society for the Promotion of Science 23H00541Japan Society for the Promotion of Science 23K17372Japan Society for the Promotion of Science 23K28408Japan Society for the Promotion of Science 24H00038Japan Society for the Promotion of Science 24K01646Japan Society for the Promotion of Science 25H00006Japan Society for the Promotion of Science 25K01896
6 · The paper itself

Abstract

Cancer peptide vaccines harness the host immune system to generate tumor-specific immune responses, offering potential for treating metastatic cancers and preventing recurrence. However, the limited immunogenicity of peptide antigens restricts their clinical efficacy, necessitating strategies to enhance their potency. One promising approach involves the conjugation of antigens with adjuvants to elicit antigen-specific immune responses, thereby creating self-adjuvanting vaccines. In this study, we developed an improved platform for such vaccines. Specifically, the antigenic CH401 peptide was conjugated with the adjuvant (Pam

Indexed as

Adjuvants, ImmunologicAntigensCancer VaccinesImmunologic FactorsNanoparticlesAnimalsHumansMiceNanovaccinesAdjuvants, ImmunologicAntigensCancer VaccinesImmunologic FactorsNanovaccinesAdjuvantDrug delivery systemLipid NanoparticleVaccine

Identifiers

PMID41403359
PMCPMC12970494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.